Fig. 6: Positive selection of GIE events beyond the HLA-I.

a, Pan-cancer dN:dS ratios of non-HLA-I genes in the metastatic (left) and primary (right) datasets. The vertical lines represent the 5% and 95% CIs after ten randomizations, and the dots the maximum likelihood estimates. b,c, Representation of gene and cancer type-specific, positive selection of non-HLA-I GIE-associated genes in the metastatic (Hartwig) (b) and primary (PCAWG) (c) cohorts. The pathway number attributed to each gene is displayed next to the gene name, relative to Fig. 1a. d, Distribution of highly focal biallelic deletions surrounding the B2M gene, spanning chromosome (chr.) 15 from 40.0-Mb to 50.1-Mb genomic ___location in the pan-cancer metastatic cohort. e, Distribution of highly focal CN amplification surrounding the SETDB1 gene, spanning chr. 1 from 145.0-Mb to 164.9-Mb genomic ___location in the metastatic NSCLC cohort. Each bin represents 100 kb. The dashed horizontal lines represent the expected mean after randomization and the vertical dashed lines highlight the gene genomic ___location.